Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 16, 2015 - Issue 4
Submit an article Journal homepage
528
Views
54
CrossRef citations to date
0
Altmetric
Drug Evaluation

Saroglitazar for the treatment of dyslipidemia in diabetic patients

Shashank R JoshiLilavati Hospital and Research Centre – Endocrinology, A - 791 Bandra Reclamation Bandra (W), Mumbai, Maharashtra 400050, [email protected]
Pages 597-606 | Published online: 12 Feb 2015

Citations (54)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Emanuel Raschi, Arianna Mazzotti, Elisabetta Poluzzi, Fabrizio De Ponti & Giulio Marchesini. (2018) Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease. Expert Opinion on Pharmacotherapy 19:17, pages 1903-1914.
Read now
Wen-Qing Jia, Zhi Jing, Xin Liu, Xiao-Yan Feng, Ya-Ya Liu, Shu-Qing Wang, Wei-Ren Xu, Jian-Wen Liu & Xian-Chao Cheng. (2018) Virtual identification of novel PPARα/γ dual agonists by scaffold hopping of saroglitazar. Journal of Biomolecular Structure and Dynamics 36:13, pages 3496-3512.
Read now
Bogusław Okopień, Lukasz Buldak & Aleksandra Bołdys. (2017) Fibrates in the management of atherogenic dyslipidemia. Expert Review of Cardiovascular Therapy 15:12, pages 913-921.
Read now

Articles from other publishers (51)

Mohammad Shadab Siddiqui, Deven Parmar, Farheen Sheikh, Shiv Kumar Sarin, Laura Cisneros, Samer Gawrieh, Taufik Momin, Ajay Duseja & Arun J. Sanyal. (2023) Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis. Clinical Gastroenterology and Hepatology 21:10, pages 2597-2605.e2.
Crossref
Xiaolin Yang, Yujing Wang, Xueqi Tang, Junfeng Wei, Xiaobo Yu, Jiefang Kang, Yong Xi & Xiaochang Xue. (2023) Corni Fructus extracts ameliorate Streptozotocin-Induced diabetes in mice via regulating AMPK/ACC/CPT-1 signaling pathway. Journal of Functional Foods 107, pages 105661.
Crossref
Sanjay Bandyopadhyay, Shambo Samrat Samajdar & Saibal Das. (2023) Effects of saroglitazar in the treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis. Clinics and Research in Hepatology and Gastroenterology 47:7, pages 102174.
Crossref
Giovanni Musso, Francesca Saba, Maurizio Cassader & Roberto Gambino. (2023) Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): Recent advances. Progress in Lipid Research 91, pages 101238.
Crossref
Sujit Chaudhuri, Agnibha Dutta & Sunil Baran Das Chakraborty. (2023) Efficacy and safety of saroglitazar in real‐world patients of non‐alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: A tertiary care center experience. JGH Open 7:3, pages 215-220.
Crossref
Mohammad Shadab Siddiqui, Deven Parmar, Farheen Shaikh, Mikael Forsgren, Samarth Patel, Anh Tuan Bui, Sherry Boyett, Vaishali Patel & Arun J. Sanyal. (2023) Saroglitazar improves nonalcoholic fatty liver disease and metabolic health in liver transplant recipients. Liver Transplantation Publish Ahead of Print.
Crossref
Vassiliki‐Panagiota Tassopoulou, Ariadni Tzara & Angeliki P. Kourounakis. (2022) Design of Improved Antidiabetic Drugs: A Journey from Single to Multitarget Agents. ChemMedChem 17:23.
Crossref
Devarapalli Ranjani Durga, Nadella Mounika, Pravallika Mudimala & Ramu Adela. (2022) Efficacy and Safety of Saroglitazar in Patients with Cardiometabolic Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Clinical Drug Investigation 42:12, pages 1049-1064.
Crossref
Manik Chhabra, Kota Vidyasagar, Sai Krishna Gudi, Jatin Sharma, Rishabh Sharma & Muhammed Rashid. (2022) Efficacy and safety of saroglitazar for the management of dyslipidemia: A systematic review and meta-analysis of interventional studies. PLOS ONE 17:7, pages e0269531.
Crossref
Aswathy R. Devan, Bhagyalakshmi Nair, Ayana R. Kumar & Lekshmi R. Nath. (2021) An insight into the role of telmisartan as PPAR‐γ/α dual activator in the management of nonalcoholic fatty liver disease. Biotechnology and Applied Biochemistry 69:2, pages 461-468.
Crossref
Banshi Saboo, Sanjay Agarwal, Brij Mohan Makkar, Rajeev Chawla, Sujoy Ghosh, Vijay Viswanathan, Sunil Gupta, Ch. Vasanth Kumar, Anuj Maheshwari, L. Sreenivasamurthy, Rakesh Kumar Sahay, Sanjay Reddy, Shalini Jaggi, Jugal Kishor Sharma, Vijay Panikar, Anand Moses, Bikash Bhattacharjee, Pratap Jethwani, Sudhir Bhandari, J. P. S. Sawhney, Shashank Joshi, Saumitra Ray, S. V. Madhu & Bipin Sethi. (2022) RSSDI consensus recommendations for dyslipidemia management in diabetes mellitus. International Journal of Diabetes in Developing Countries 42:1, pages 3-28.
Crossref
Lucia Parlati, Marion Régnier, Hervé Guillou & Catherine Postic. (2021) New targets for NAFLD. JHEP Reports 3:6, pages 100346.
Crossref
Mohammad Shadab Siddiqui, Michael O. Idowu, Deven Parmar, Brian B. Borg, Douglas Denham, Nicole M. Loo, Donald Lazas, Ziad Younes & Arun J. Sanyal. (2021) A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology 19:12, pages 2670-2672.
Crossref
Suvadeep Mal, Ashish Ranjan Dwivedi, Vijay Kumar, Naveen Kumar, Bhupinder Kumar & Vinod Kumar. (2021) Role of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) in Different Disease States: Recent Updates. Current Medicinal Chemistry 28:16, pages 3193-3215.
Crossref
Amit Joharapurkar, Vishal Patel, Samadhan Kshirsagar, Maulik S. Patel, Hardikkumar Savsani & Mukul Jain. (2021) Effect of dual PPAR-α/γ agonist saroglitazar on diabetic retinopathy and oxygen-induced retinopathy. European Journal of Pharmacology 899, pages 174032.
Crossref
Mohammad Said Ramadan, Vincenzo Russo, Gerardo Nigro, Emanuele Durante-Mangoni & Rosa Zampino. (2021) Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective. Journal of Clinical Medicine 10:8, pages 1569.
Crossref
Niki Katsiki & Christos Mantzoros. (2021) Making progress towards a better pathophysiological understanding and more promising therapeutic options for treating non-alcoholic steatohepatitis (NASH)/DASH (dysmetabolism associated steatohepatitis). Metabolism 114, pages 154333.
Crossref
Manjunath Krishnappa, Kishor Patil, Krupi Parmar, Purav Trivedi, Nirali Mody, Chintan Shah, Khushboo Faldu, Sanjay Maroo, Piyush Desai, Kamlesh Fatania, Satyanarayan Murthy, R. Balamurugan, Manish Agarwal, K. P. Singh, G. S. Kalra, Vipul Khandelwal, Ashish Singwala, Hemant Thacker, Rahul Tulle, Harish Rao, Mukund Kumbla, Parminder Singh, Ashok Khatri, Sumit Agrawal, R. N. Sarkar, Dinesh Agarwal, Girish Bhatia, R. P. Agarwal, Surender Kumar, P. R. Vamsi Krishna, Ajay Kumar Ajmani, Amit Asalkar, Indraneel Basu, Sudip Chatterjee, Vinod Kumar Pavithran, Rupam Das, Aniruddha Dharmadhikari, Vikram Vardhan, M. Madusudhan Babu, Nilanjan Sengupta, Srirang Abkari, R. Harikrishna, Rashmi Chovatia & Deven Parmar. (2020) Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study). Cardiovascular Diabetology 19:1.
Crossref
Ashu Rastogi, Richard L. Dunbar, Hemant P. Thacker, Jayesh Bhatt, Krupi Parmar & Deven V. Parmar. (2020) Abrogation of postprandial triglyceridemia with dual PPAR α/γ agonist in type 2 diabetes mellitus: a randomized, placebo-controlled study. Acta Diabetologica 57:7, pages 809-818.
Crossref
Divya P. Kumar, Rebecca Caffrey, Jonathon Marioneaux, Prasanna K. Santhekadur, Madhavi Bhat, Cristina Alonso, Srinivas V. Koduru, Binu Philip, Mukul R. Jain, Suresh R. Giri, Pierre Bedossa & Arun J. Sanyal. (2020) The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease. Scientific Reports 10:1.
Crossref
Sayak Roy. (2020) Clinical Case Series of Decrease in Shear Wave Elastography Values in Ten Diabetic Dyslipidemia Patients Having NAFLD with Saroglitazar 4 mg: An Indian Experience. Case Reports in Medicine 2020, pages 1-4.
Crossref
Raymond E. Soccio. 2020. The Liver. The Liver 337 350 .
Marialuigia Fantacuzzi, Barbara De Filippis, Rosa Amoroso & Letizia Giampietro. (2019) PPAR Ligands Containing Stilbene Scaffold. Mini-Reviews in Medicinal Chemistry 19:19, pages 1599-1610.
Crossref
Upendra Kaul, Deven Parmar, K. Manjunath, Mitesh Shah, Krupi Parmar, Kishor P. Patil & Ashok Jaiswal. (2019) New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence. Cardiovascular Diabetology 18:1.
Crossref
Mirhan N. Makled, Maha H. Sharawy & Mohammed S. El-Awady. (2019) The dual PPAR-α/γ agonist saroglitazar ameliorates thioacetamide-induced liver fibrosis in rats through regulating leptin. Naunyn-Schmiedeberg's Archives of Pharmacology 392:12, pages 1569-1576.
Crossref
Narendra S. Choudhary, Naveen Kumar & Ajay Duseja. (2019) Peroxisome Proliferator-Activated Receptors and Their Agonists in Nonalcoholic Fatty Liver Disease. Journal of Clinical and Experimental Hepatology 9:6, pages 731-739.
Crossref
Pitchai Balakumar, Nanjaian Mahadevan & Ramanathan Sambathkumar. (2019) A Contemporary Overview of PPARα/γ Dual Agonists for the Management of Diabetic Dyslipidemia. Current Molecular Pharmacology 12:3, pages 195-201.
Crossref
Li-Chun Chen, Zhong-Yang Fan, Hong-Yu Wang, Dong-Cheng Wen & Shi-Yu Zhang. (2019) Effect of polysaccharides from adlay seed on anti-diabetic and gut microbiota. Food & Function 10:7, pages 4372-4380.
Crossref
Fan Hong, Shijia Pan, Yuan Guo, Pengfei Xu & Yonggong Zhai. (2019) PPARs as Nuclear Receptors for Nutrient and Energy Metabolism. Molecules 24:14, pages 2545.
Crossref
Noha F. Hassan, Somaia A. Nada, Azza Hassan, Mona R. El-Ansary, Muhammad Y. Al-Shorbagy & Rania M. Abdelsalam. (2019) Saroglitazar Deactivates the Hepatic LPS/TLR4 Signaling Pathway and Ameliorates Adipocyte Dysfunction in Rats with High-Fat Emulsion/LPS Model-Induced Non-alcoholic Steatohepatitis. Inflammation 42:3, pages 1056-1070.
Crossref
Josephine Skat‐Rørdam, David Højland Ipsen, Jens Lykkesfeldt & Pernille Tveden‐Nyborg. (2019) A role of peroxisome proliferator‐activated receptor γ in non‐alcoholic fatty liver disease. Basic & Clinical Pharmacology & Toxicology 124:5, pages 528-537.
Crossref
Youn, Ham, Yoon, Choi, Lee, Cho & Kim. (2019) Cynanchum wilfordii Etanolic Extract Controls Blood Cholesterol: A Double-blind, Randomized, Placebo-Controlled, Parallel Trial. Nutrients 11:4, pages 836.
Crossref
Mohammad Javad Saeedi Borujeni, Ebrahim Esfandiary, Mustafa Ghanadian, Ali Valiani, Azar Baradaran & Amid Yazdani. (2018) Alterations in lipid peroxidation, lipid profile, insulin sensitivity, and hepatic histopathological changes in diabetic rats following the treatment with Salvadora persica . Journal of Cellular Biochemistry 120:3, pages 3696-3708.
Crossref
Ying Kong, Yan Gao, Dongyi Lan, Ying Zhang, Rixin Zhan, Meiqi Liu, Zhouan Zhu, Guohua Zeng & Qiren Huang. (2019) Trans-repression of NFκB pathway mediated by PPARγ improves vascular endothelium insulin resistance. Journal of Cellular and Molecular Medicine 23:1, pages 216-226.
Crossref
William P. Esler & Kendra K. Bence. (2019) Metabolic Targets in Nonalcoholic Fatty Liver Disease. Cellular and Molecular Gastroenterology and Hepatology 8:2, pages 247-267.
Crossref
Giovanni Musso, Maurizio Cassader, Elena Paschetta & Roberto Gambino. (2018) Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis. Gastroenterology 155:2, pages 282-302.e8.
Crossref
Fan Hong, Pengfei Xu & Yonggong Zhai. (2018) The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development. International Journal of Molecular Sciences 19:8, pages 2189.
Crossref
Mukul R. Jain, Suresh R. Giri, Bibhuti Bhoi, Chitrang Trivedi, Akshyaya Rath, Rohan Rathod, Ramchandra Ranvir, Shekhar Kadam, Hiren Patel, Prabodha Swain, Sib Sankar Roy, Nabanita Das, Eshani Karmakar, Walter Wahli & Pankaj R. Patel. (2018) Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models. Liver International 38:6, pages 1084-1094.
Crossref
Michel P. Hermans & Paul Valensi. (2018) Elevated triglycerides and low high-density lipoprotein cholesterol level as marker of very high risk in type 2 diabetes. Current Opinion in Endocrinology & Diabetes and Obesity 25:2, pages 118-129.
Crossref
M.J. Nanjan, Manal Mohammed, B.R. Prashantha Kumar & M.J.N. Chandrasekar. (2018) Thiazolidinediones as antidiabetic agents: A critical review. Bioorganic Chemistry 77, pages 548-567.
Crossref
Shuchi N. Joshi, Nuggehally R. Srinivas & Deven V. Parmar. (2018) Limited Sampling Strategy for Accurate Prediction of Pharmacokinetics of Saroglitazar: A 3-point Linear Regression Model Development and Successful Prediction of Human Exposure. Clinical Therapeutics 40:3, pages 456-468.e1.
Crossref
Pegah Golabi, Haley Bush & Zobair M. Younossi. (2017) Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Clinics in Liver Disease 21:4, pages 739-753.
Crossref
Lu Han, Wen-Jun Shen, Stefanie Bittner, Fredric B Kraemer & Salman Azhar. (2017) PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-α. Future Cardiology 13:3, pages 259-278.
Crossref
Barbara Gross, Michal Pawlak, Philippe Lefebvre & Bart Staels. (2016) PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. Nature Reviews Endocrinology 13:1, pages 36-49.
Crossref
Mariela Glandt & Zachary Bloomgarden. 2017. Principles of Diabetes Mellitus. Principles of Diabetes Mellitus 999 1012 .
Nguan Soon Tan, Manuel Vázquez-Carrera, Alexandra Montagner, Ming Keat Sng, Hervé Guillou & Walter Wahli. (2016) Transcriptional control of physiological and pathological processes by the nuclear receptor PPARβ/δ. Progress in Lipid Research 64, pages 98-122.
Crossref
Jonathan D. Schofield, Yifen Liu, Prasanna Rao-Balakrishna, Rayaz A. Malik & Handrean Soran. (2016) Diabetes Dyslipidemia. Diabetes Therapy 7:2, pages 203-219.
Crossref
Maria Talla, Gerry McKay & Miles Fisher. (2016) Saroglitazar. Practical Diabetes 33:4, pages 142-143a.
Crossref
Giovanni Musso, Maurizio Cassader & Roberto Gambino. (2016) Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nature Reviews Drug Discovery 15:4, pages 249-274.
Crossref
Maurizio Vitti, Giovanna Di Emidio, Michela Di Carlo, Gaspare Carta, Andrea Antonosante, Paolo Giovanni Artini, Annamaria Cimini, Carla Tatone & Elisabetta Benedetti. (2016) Peroxisome Proliferator-Activated Receptors in Female Reproduction and Fertility. PPAR Research 2016, pages 1-12.
Crossref
Mariela Glandt & Zachary Bloomgarden. 2016. Principles of Diabetes Mellitus. Principles of Diabetes Mellitus 1 14 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.